Spyre Therapeutics, Inc. (SYRE)

Market Cap	1.22B
Revenue (ttm)	886,000
Net Income (ttm)	-338.79M
Shares Out	36.15M
EPS (ttm)	-49.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,248
Open	34.10
Previous Close	35.58
Day's Range	33.56 - 35.40
52-Week Range	2.65 - 47.97
Beta	2.85
Analysts	Strong Buy
Price Target	38.00 (+12.94%)
Earnings Date	May 9, 2024

About SYRE

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7)...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2016
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: SYRE

Financial Performance

In 2023, SYRE's revenue was $886,000, a decrease of -61.96% compared to the previous year's $2.33 million. Losses were -$338.79 million, 304.2% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price forecast is $38.0, which is an increase of 12.94% from the latest price.

Price Target

$38.0

(12.94% upside)

Analyst Consensus: Strong Buy